Fresenius

Some brighter views

21/06/22 -"We have revised our models and included all figures. We have become more optimistic about Kabi’s profitability (IV drug’s brake to earnings sorted) and allowed for Helios’ higher than anticipated ..."

PDF page sample
Pages
57
Language
English
Published on
21/06/22
Download
You may also be interested by these reports :
28/06/22
Philips shared the results of tests conducted on a sample of sleep apnea devices from the US and Canada, wherein the majority of the devices passed ...
28/06/22
Following the availability of the formal annual report, we have integrated the audited FY21 actual figures which were consistent with the preliminary ...
21/06/22
We have revised our models and included all figures. We have become more optimistic about Kabi’s profitability (IV drug’s brake to earnings sorted) ...
21/06/22
With the double-whammy of waning pandemic-driven opportunities and the markets becoming increasingly-wary of high P/E MedTechs, testing stocks are ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO